New hope for tough bladder cancer: phase 3 trial launches for SYS6002
NCT ID NCT07526792
First seen Apr 18, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This phase 3 trial tests a new drug called SYS6002 against standard chemotherapy in about 406 people with advanced bladder cancer that has not responded to platinum chemotherapy and immunotherapy. The main goal is to see if SYS6002 helps people live longer. The study is not yet recruiting and requires participants aged 18-75 whose cancer has worsened after prior treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.